Inside Oncology: Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More
Approval of lenvatinib for differentiated thyroid cancer, the approval of frontline lenalidomide and positive findings for ixazomib in multiple myeloma, and a newly launched oncology care model by Med...
Author: onclivetv
Added: 02/25/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 25, 2015 Category: Cancer & Oncology Source Type: podcasts
The Approval of Lenalidomide in Multiple Myeloma
Dr. Sundar Jagannath discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.
Sundar Jagannath, MD, director of the multiple myeloma program, professor of medi...
Author: onclivetv
Added: 02/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr.Ruan Discusses Lenalidomide Plus Rituximab in MCL
Sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma.
Jia Ruan, MD, PhD, is an associate professor at ...
Author: onclivetv
Added: 02/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr. Kumar discusses Ixazomib Combo for Multiple Myeloma Treatment
Dr. Kumar discusses the use of the proteasome inhibitor Ixazomib in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Shaji Kumar, MD, ...
Author: onclivetv
Added: 02/24/2015 (Source: Oncology Tube)
Source: Oncology Tube - February 24, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Ola Landgren at ASH 2014: Final results from NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in high-risk smouldering myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren discusses the final results from the NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in 12 pati...
Author: EMJ
Added: 01/13/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 13, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Jeffery Matous at ASH 2014: Phase III ASPIRE study of carfilzomib, lenalidomide and dexamethasone in relapsed myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Jeffery Matous ((Colorado Blood Cancer Institute, Denver, CO) discusses the randomised, open-label, multicentre phase III ASPIRE stu...
Author: EMJ
Added: 01/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2015 Category: Cancer & Oncology Source Type: podcasts
Dr Maria-Victoria Mateos at ASH 2014: Follow up on a phase III study of lenalidomide plus low-dose dexamethasone in high-risk smouldering myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Maria-Victoria Mateos provides an update of a randomised, phase III study, which was initiated in 2007, of lenalidomide plus low-dos...
Author: EMJ
Added: 01/09/2015 (Source: Oncology Tube)
Source: Oncology Tube - January 9, 2015 Category: Cancer & Oncology Source Type: podcasts
R-squared Update: Underwhelms in FL, but Impressive in MCL
Dr Bruce Cheson and Dr Nathan Fowler discuss lenalidomide clinical trial results at the 2014 ASH meeting, focusing on a trial presented by the Nordic Lymphoma Group. (Source: Medscape Oncology)
Source: Medscape Oncology - December 15, 2014 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
ASH 2014: Phase Ib dose escalation trial of SAR650984 (anti-CD38 monoclonal antibody) in combination with lenalidomide and dexamethasone improves overall response rate and clinical benefit response in relapsed or refractory myeloma
At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Thomas Martin (University of California San Francisco, San Francisco, CA) discusses a phase Ib dose esca...
Author: EMJ
Added: 12/09/2014 (Source: Oncology Tube)
Source: Oncology Tube - December 9, 2014 Category: Cancer & Oncology Source Type: podcasts
Case 1: Standard-risk, Younger Double Refractory Patient
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2014 Category: Cancer & Oncology Source Type: podcasts
Case 2: Double Refractory Patient with High-risk Cytogenetics
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2014 Category: Cancer & Oncology Source Type: podcasts
Case 3: Elderly Double Refractory Patient with Renal Impairment
Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen...
Author: imedex
Added: 06/05/2014 (Source: Oncology Tube)
Source: Oncology Tube - June 5, 2014 Category: Cancer & Oncology Source Type: podcasts
Multiple Myeloma - Case Presentations
Dr. James Berenson discusses two cases: 1) a myeloma patient who has relapsed after frontline therapy, and 2) a myeloma patient who is refractory to both bortezomib and lenalidomide.
This webcast w...
Author: imedex
Added: 01/18/2014 (Source: Oncology Tube)
Source: Oncology Tube - January 19, 2014 Category: Cancer & Oncology Source Type: podcasts
Treatment Response Rates Following a Myeloma Relapse
Will certain myeloma drugs respond well if used again for relapse? A patient poses a question about relapse and whether Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasonealone (Decadron) ...
Author: patientpower
Added: 12/12/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 13, 2013 Category: Cancer & Oncology Source Type: podcasts
ASH 2013: Lymphoma - Lenalidomide
Drs. Ravandi-Kashani, Czuczman, Steensma, Cortes, Anderson, and Brown comprise the faculty for this compelling group of Best of the Day interviews with Dr. Jim Epstein as moderator. These internationa...
Author: imedex
Added: 12/12/2013 (Source: Oncology Tube)
Source: Oncology Tube - December 12, 2013 Category: Cancer & Oncology Source Type: podcasts
